Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study
Background Both critically ill patients with coronavirus disease 2019 (COVID-19) and patients receiving extracorporeal membrane oxygenation (ECMO) support exhibit a high incidence of healthcare-associated infections (HAI). However, data on incidence, microbiology, resistance patterns, and the impact of HAI on outcomes in patients receiving ECMO for severe COVID-19 remain limited. We aimed to report HAI incidence and microbiology in patients receiving ECMO for severe COVID-19 and to evaluate the impact of ECMO-associated infections (ECMO-AI) on in-hospital mortality. Methods For this study, we analyzed data from 701 patients included in the ECMOSARS registry which included COVID-19 patients supported by ECMO in France. Results Among 602 analyzed patients for whom HAI and hospital mortality data were available, 214 (36%) had ECMO-AI, resulting in an incidence rate of 27 ECMO-AI per 1000 ECMO days at risk. Of these, 154 patients had bloodstream infection (BSI) and 117 patients had ventilator-associated pneumonia (VAP). The responsible microorganisms were Enterobacteriaceae (34% for BSI and 48% for VAP), Enterococcus species (25% and 6%, respectively) and non-fermenting Gram-negative bacilli (13% and 20%, respectively). Fungal infections were also observed (10% for BSI and 3% for VAP), as were multidrug-resistant organisms (21% and 15%, respectively). Using a Cox multistate model, ECMO-AI were not found associated with hospital death (HR = 1.00 95% CI [0.79–1.26], p = 0.986). Conclusions In a nationwide cohort of COVID-19 patients receiving ECMO support, we observed a high incidence of ECMO-AI. ECMO-AI were not found associated with hospital death. Trial registration number NCT04397588 (May 21, 2020)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Critical care - 28(2024), 1 vom: 20. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nesseler, Nicolas [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Bloodstream infections |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13054-024-04832-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05482642X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05482642X | ||
| 003 | DE-627 | ||
| 005 | 20240220064729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-024-04832-3 |2 doi | |
| 035 | |a (DE-627)SPR05482642X | ||
| 035 | |a (SPR)s13054-024-04832-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nesseler, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Both critically ill patients with coronavirus disease 2019 (COVID-19) and patients receiving extracorporeal membrane oxygenation (ECMO) support exhibit a high incidence of healthcare-associated infections (HAI). However, data on incidence, microbiology, resistance patterns, and the impact of HAI on outcomes in patients receiving ECMO for severe COVID-19 remain limited. We aimed to report HAI incidence and microbiology in patients receiving ECMO for severe COVID-19 and to evaluate the impact of ECMO-associated infections (ECMO-AI) on in-hospital mortality. Methods For this study, we analyzed data from 701 patients included in the ECMOSARS registry which included COVID-19 patients supported by ECMO in France. Results Among 602 analyzed patients for whom HAI and hospital mortality data were available, 214 (36%) had ECMO-AI, resulting in an incidence rate of 27 ECMO-AI per 1000 ECMO days at risk. Of these, 154 patients had bloodstream infection (BSI) and 117 patients had ventilator-associated pneumonia (VAP). The responsible microorganisms were Enterobacteriaceae (34% for BSI and 48% for VAP), Enterococcus species (25% and 6%, respectively) and non-fermenting Gram-negative bacilli (13% and 20%, respectively). Fungal infections were also observed (10% for BSI and 3% for VAP), as were multidrug-resistant organisms (21% and 15%, respectively). Using a Cox multistate model, ECMO-AI were not found associated with hospital death (HR = 1.00 95% CI [0.79–1.26], p = 0.986). Conclusions In a nationwide cohort of COVID-19 patients receiving ECMO support, we observed a high incidence of ECMO-AI. ECMO-AI were not found associated with hospital death. Trial registration number NCT04397588 (May 21, 2020). | ||
| 650 | 4 | |a ECLS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV 2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nosocomial infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ventilator-associated pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bloodstream infections |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mansour, Alexandre |4 aut | |
| 700 | 1 | |a Schmidt, Matthieu |4 aut | |
| 700 | 1 | |a Para, Marylou |4 aut | |
| 700 | 1 | |a Porto, Alizée |4 aut | |
| 700 | 1 | |a Falcoz, Pierre-Emmanuel |4 aut | |
| 700 | 1 | |a Mongardon, Nicolas |4 aut | |
| 700 | 1 | |a Fougerou, Claire |4 aut | |
| 700 | 1 | |a Ross, James T. |4 aut | |
| 700 | 1 | |a Beurton, Antoine |4 aut | |
| 700 | 1 | |a Gaide-Chevronnay, Lucie |4 aut | |
| 700 | 1 | |a Guinot, Pierre-Grégoire |4 aut | |
| 700 | 1 | |a Lebreton, Guillaume |4 aut | |
| 700 | 1 | |a Flecher, Erwan |4 aut | |
| 700 | 1 | |a Vincentelli, André |4 aut | |
| 700 | 1 | |a Massart, Nicolas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care |d London : BioMed Central, 1997 |g 28(2024), 1 vom: 20. Feb. |w (DE-627)SPR029726166 |w (DE-600)2051256-9 |x 1364-8535 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:1 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13054-024-04832-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 1 |b 20 |c 02 | ||